flow trial semaglutide kidney outcomes results 2024 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators flow trial semaglutide results Effects

Real Results

Longevity NAD+ injection Cellular energy and cognitive support

16 Matthias Tschp and his team discovered that dual agonists targeting both GLP-1 and GIP receptors (GIPR) are more effective in treating diabetes than those targeting only GLP-1R

It does not predict your response to Zepbound or determine your dose

Expiry / BUD Consume within 6 months of compounding

Because injection bypasses the digestive tract, it also introduces the risk of injecting a contaminated or improperly reconstituted solution directly into tissue one reason sterile handling and correct reconstitution matter so much in research settings